Abstract: The invention provides phoH homolog polypeptides and DNA (RNA) encoding phoH homolog polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing phoH homolog polypeptides to screen for antibacterial compounds.

Abstract: The invention provides gbpA polypeptides and DNA (RNA) encoding gbpA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gbpA polypeptides to screen for antibacterial compounds.

Abstract: The invention provides respiratory nitrate reductase alpha subunit polypeptides and polynucleotides encoding respiratory nitrate reductase alpha subunit polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing respiratory nitrate reductase alpha subunit polypeptides to screen for antibacterial compounds.

Abstract: A stable sustained release theophylline formulation is prepared by incorporating theophylline into a semi-solid matrix comprising polyglycolized glycerides (GELUCIRE® excipient) and a mixture of nucleation enhancers. Theophylline is admixed with molten GELUCIRE to make the sustained release formulation. The nucleation enhancer composition is then incorporated in the admixture to make the sustained release formulation resistant to changes in dissolution upon aging. Orally administrable compositions are prepared by filling gelatin capsules with the formulation. The polyglycolized glycerides (GELUCIRE) and the nucleation enhancer composition also can be used as an excipient system for preparing sustained release pharmaceutical compositions.

Abstract: The present invention is directed to quinoline-containing .alpha.-ketoamide inhibitors of cysteine and serine proteases are disclosed. Methods for making these compounds, and methods for using the same are also disclosed.

Abstract: The invention provides leuS polypeptides and DNA (RNA) encoding leuS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing leuS polypeptides to screen for antibacterial compounds.

Abstract: The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.

Abstract: The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

Abstract: The invention relates to Arginase II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

Abstract: The invention provides alaS polypeptides and DNA (RNA) encoding alaS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing alaS polypeptides to screen for antibacterial compounds.

Abstract: This invention relates to libraries of non-peptide compounds each comprised of a core structure and methods for making such libraries. This invention also relates to novel silicon-based polymer resins and silane linkers, methods for their preparation and their use in the synthesis of libraries of compounds to be screened as pharmaceutical agents.

Abstract: The invention provides aspS polypeptides and DNA (RNA) encoding aspS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aspS polypeptides to screen for antibacterial compounds.

Abstract: The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.

Abstract: This invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier, an angiotensin II receptor antagonist and a second agent selected from a diuretic, a calcium channel blocker, a .beta.-adrenoceptor blocker, a renin inhibitor, or an angiotensin converting enzyme inhibitor and a method of treating hypertension.

Abstract: This invention relates to the novel pyrazole compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of inhibiting cytokines by a compound of Formula (I) and the treatment of cytokine mediated diseases, in mammals, by administration of said compound.

Abstract: A reminder device for notifying a user when to take a dosage of medication. The credit card size device includes a first time counter for maintaining an elapsed program time and a second time counter for maintaining a current interval time. An alarm notifies the user of the expiration of the current interval. The user takes a dosage of medication in response to the alarm. A switch is provided for resetting the second time counter after the user takes a dosage of medication.

Abstract: This invention relates to a method of inhibiting platelet aggregation using 1,4-diazocine compounds which are mimics of the peptide sequence Arg--Gly--Asp.

Abstract: Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Abstract: This invention relates to the novel compounds and pharmaceutical compositions of Formulas (I) and (II).This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).